Use of chemotherapy for patients with bone and soft-tissue sarcomas

Cleveland Clinic Journal of Medicine

Volumn 77, Issue SUPPL. 1, 2010, Pages

  Wesolowski, Robert ^a   Budd, George Thomas ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,3 DIOXOLANE DERIVATIVE; ANTINEOPLASTIC AGENT; TETRAHYDROISOQUINOLINE DERIVATIVE; TRABECTEDIN;

ADJUVANT CHEMOTHERAPY; BONE TUMOR; HUMAN; MUSCLE TUMOR; OSTEOSARCOMA; REVIEW; SARCOMA;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DIOXOLES; HUMANS; MUSCLE NEOPLASMS; OSTEOSARCOMA; SARCOMA; TETRAHYDROISOQUINOLINES;

EID: 77953149377     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.77.s1.05     Document Type: Article

References (28)

1. Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience. J Clin Oncol 1992; 10:5-15.
2. Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O. Hema-togenous micrometastases in osteosarcoma patients. Clin Cancer Res 2005; 11:4666-4673.
3. Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ, eds. Cancer Management: A Multidisciplinary Approach. 11th ed. Manhasset, NY: CMP Medica; 2009.
4. Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med 1986; 314:1600-1606.
5. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 1987; 5:21-26.
6. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23:2004-2011.
7. Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcomas: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol 1988; 6:329-337.
8. Bramwell VH, Steward WP, Nooij M, et al. Neoadjuvant chemotherapy with doxorubicin and cisplatin in malignant fibrous histiocytoma of bone: a European Osteosarcoma Intergroup study. J Clin Oncol 1999; 17:3260-3269.
9. Kager L, Zoubek A, Pötschger U, et al. Primary metastatic osteosar-coma: presentation and outcome of patients treated on Neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21:2011-2018.
10. Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother 2001; 13:324-330.
11. Nesbit ME Jr, Gehan EA, Burgert EO Jr, et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8:1664-1674.
12. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348:694-701.
13. Womer RB, West DC, Krailo MD, et al; for the Children's Oncology Group AEWS0031 Committee. Randomized comparison of every-two-week v. every-three-week chemotherapy in Ewing sarcoma family tumors. J Clin Oncol 2008; 26(May 20 suppl):10504. Abstract.
14. Rodriguez-Galindo C, Poquette CA, Marina NM, et al. Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J Pediatr Hematol Oncol 2000; 22:321-329.
15. Brade WP, Herdrich, K, Kachel-Fischer U, Araujo CE. Dosing and side-effects of ifosfamide plus mesna. J Cancer Res Clin Oncol 1991; 117(suppl 4):S164-S186.
16. Healey JH, Lane JM. Chondrosarcoma. Clin Orthop Relat Res 1986; 204:119-129.
17. Clark MA, Fisher C, Judson I, Thomas JM. Soft-tissue sarcomas in adults. N Engl J Med 2005; 353:701-711.
18. Alexander J, Dainiak N, Berger HJ, et al. Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 1979; 300:278-283.
19. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochim Biophys Acta 1998; 1400:233-255.
20. Postma TJ, Vermorken JB, Liefting AJ, Pinedo HM, Heimans JJ. Paclitaxel-induced neuropathy. Ann Oncol 1995; 6:489-494.
21. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997; 350:1647-1654.
22. Woll PJ, van Glabbeke M, Hohenberger P, et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial. J Clin Oncol 2007; 25(June 20 suppl):10008. Abstract.
23. Grobmyer SR, Maki RG, Demetri GD, et al. Neo-adjuvant chemo therapy for primary high-grade extremity soft tissue sarcoma. Ann Oncol 2004; 15:1667-1672.
24. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001; 37:1096-1103.
25. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005; 23:5484-5492.
26. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004; 22:890-899.
27. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004; 22:1480-1490.
28. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005; 23:576-584.